Lv3
218 积分 2023-11-07 加入
Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy
2天前
已完结
Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies
3天前
已完结
Cardiovascular Safety Across Leading BTK Inhibitors in Relapsed/Refractory CLL: Results of a Network Meta‐Analysis
3天前
已完结
Efficacy and Safety of Autologous Stem Cell Transplantation in First-Line Treatment and at Relapse in Elderly Patients with Multiple Myeloma
1个月前
已完结
SOHO State of the Art Updates and Next Questions: Will CAR-T Replace ASCT in NDMM
1个月前
已完结
Classic Hodgkin Lymphoma in the Older Adult
1个月前
已关闭
Quadruplet daratumumab in combination with bortezomib, lenalidomide, and dexamethasone as front-line regimen improved clinical outcomes in high-risk myeloma patients in China: a multi-centered prospective real-world study
1个月前
已完结
Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ study
2个月前
已关闭
53P Distinct cellular and molecular patterns in pre-treatment peripheral blood are associated with CAR-T outcomes in diffuse large B-cell lymphoma
6个月前
已关闭
Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy
6个月前
已关闭
皖公网安备34019202002308
